Following a positive opinion from the European Medicines Agency (EMEA ) in February 2008, the Commission last week granted market authorisation for Prepandrix™ – the first pre-pandemic vaccine for humans against influenza caused by the H5N1 virus.
Bringing regions together for better health
GET THE LATEST FROM EUREGHA IN YOUR INBOX!
If you want to receive the quarterly EUREGHA newsletters and staying updated on our events, projects and more, you may opt-in by clicking on the button here to the right!
The EUREGHA Secretariat will treat your data only for the purpose mentioned here.
